Classes of Anti-HIV-1 Therapeutics: From FDA-approved Drugs to Hypothetical Future Targets
Class/Target | Example | |
---|---|---|
1Date of FDA approval | ||
FDA Approved | ||
Reverse Transcriptase (RT) inhibitors | ||
Nucleoside analog RT inhibitors (NRTI) | AZT (zidovudine) (1987)1 | |
Non-nucleoside RT inhibitors (NNRTI) | Nevirapine (1996) | |
Protease (PR) inhibitors | Saquinavir (1995) | |
Entry/fusion inhibitors | ||
Gp41-based | T20 (Enfuvirtide) (2003) | |
CCR5-based | Maraviroc (2007) | |
Integrase (IN) inhibitors | Raltegravir (2007) | |
In Clinical Trials | ||
Gag-processing-based maturation inhibitors | Bevirimat | |
Under Development | ||
RNaseH inhibitors | ||
Capsid (CA)-based maturation inhibitors | ||
Budding inhibitors | ||
LEDGF-based inhibitors | ||
Vpu/tetherin-based inhibitors | ||
Vif/APOBEC3G-based inhibitors | ||
CA/TRIM5α-based inhibitors |